Sarah Cannon Research Institute
Carissa Jones has a diverse work experience spanning different roles and organizations. Carissa currently works as an Associate Director of Personalized Medicine Operations at Sarah Cannon Research Institute since 2023. Before that, they held positions at Sarah Cannon as a Senior Program Specialist and Program Specialist for Personalized Medicine from 2018 to 2022. Prior to this, they were a Postdoctoral Research Fellow at Vanderbilt University Medical Center, focusing on genetic ancestry and identifying genetic risk factors for lung cancer. Carissa also worked as a Scientist in the Classroom Program Fellow at Vanderbilt University, where they partnered with a middle school teacher to conduct engineering-based labs with students. Additionally, they have experience as a Student Success Center Peer Tutor and Biology Lab Teaching Assistant at Palm Beach Atlantic University. Carissa also served as a Summer Undergraduate Research Fellow at The Scripps Research Institute.
Carissa Jones pursued their education in a chronological manner, starting with their undergraduate studies at Palm Beach Atlantic University from 2008 to 2012. During this time, they obtained a Bachelor of Science (B.S.) degree in Medicinal and Biological Chemistry. Following their undergraduate studies, Carissa went on to attend Vanderbilt University School of Medicine from 2012 to 2017. During this period, they pursued a Doctor of Philosophy (Ph.D.) degree in Human Genetics.
This person is not in any teams
Sarah Cannon Research Institute
Sarah Cannon Research Institute (SCRI) is one of the world’s leading oncology research organizations conducting community-based clinical trials. In 2022, SCRI formed a joint venture with former US Oncology Research to enhance clinical trial access and availability across the country. Focused on advancing therapies for patients over the last three decades, SCRI is a leader in drug development. It has conducted nearly 700 first-in-human clinical trials since its inception and contributed to pivotal research that has led to the majority of new cancer therapies approved by the FDA today. The combined research network brings together physicians who are actively accruing patients to clinical trials at more than 250 locations in 26 states across the US.